Press Releases

Press Releases

Company Reaches Consensus with FDA on Key Aspects of Novel Pivotal Phase 3 Study Agency Guidance May Provide Significant Time- and Cost-Efficiency for Phase 3 Program Approximately 17 Million American Adults Suffer from Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif., July 23, 2020 /PRNewswire/
VistaGen Eligible to Receive up to $177 Million, Including Upfront and Potential Milestone Payments, in Addition to Royalties, under PH94B License in Key Asian Markets Announced Subsequent to Fiscal 2020 Year End SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ --  VistaGen Therapeutics
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets Agreement includes $5 million upfront payment and development and commercial milestones up to $172 million SOUTH SAN FRANCISCO, Calif. and SHANGHAI, June 25, 2020 /PRNewswire/ --  VistaGen
Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior Delivery, an Enhanced Therapeutic Profile and Additional Intellectual Property Protection SOUTH SAN FRANCISCO, Calif., May 27, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage
The Proposed Phase 2A Open-label Study will be Conducted in New York City SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain
Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) SOUTH SAN FRANCISCO, Calif., April 28, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines
SOUTH SAN FRANCISCO, Calif., March 25, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical need, today
PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ --  VistaGen Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial results for
When given together with VistaGen's oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical
Displaying 61 - 70 of 199